The 2016 headliner for Teva Pharmaceutical Industries was its acquisition of Actavis Generics, which sent $33.43 billion in cash and about 100 million Teva shares to Allergan.
The Kenilworth, New Jersey, company expects 2017 to produce the same worldwide sales scenario as last year. Yet despite the cautious outlook, stock prices are hovering higher than they were at this time in 2016.
After mulling over M&A options, Johnson & Johnson sprang into action in pursuit of Swiss biotech Actelion and initially received muted applause from investors.